Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient

Author(s):  
Runbo Zhong ◽  
Yunbin Zhang ◽  
Dongfang Chen ◽  
Shuhui Cao ◽  
Baohui Han ◽  
...  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Zhi-Xiong Chong ◽  
Wan-Yong Ho ◽  
Swee-Keong Yeap ◽  
Mong-Lien Wang ◽  
Yueh Chien ◽  
...  

2022 ◽  
Vol 7 (1) ◽  
Author(s):  
Li Zhang ◽  
Yiming Zhang ◽  
Chengdi Wang ◽  
Ying Yang ◽  
Yinyun Ni ◽  
...  

AbstractLung adenocarcinoma (LUAD) and squamous carcinoma (LUSC) are two major subtypes of non-small cell lung cancer with distinct pathologic features and treatment paradigms. The heterogeneity can be attributed to genetic, transcriptional, and epigenetic parameters. Here, we established a multi-omics atlas, integrating 52 single-cell RNA sequencing and 2342 public bulk RNA sequencing. We investigated their differences in genetic amplification, cellular compositions, and expression modules. We revealed that LUAD and LUSC contained amplifications occurring selectively in subclusters of AT2 and basal cells, and had distinct cellular composition modules associated with poor survival of lung cancer. Malignant and stage-specific gene analyses further uncovered critical transcription factors and genes in tumor progression. Moreover, we identified subclusters with proliferating and differentiating properties in AT2 and basal cells. Overexpression assays of ten genes, including sub-cluster markers AQP5 and KPNA2, further indicated their functional roles, providing potential targets for early diagnosis and treatment in lung cancer.


Cell ◽  
2020 ◽  
Vol 182 (5) ◽  
pp. 1232-1251.e22 ◽  
Author(s):  
Ashley Maynard ◽  
Caroline E. McCoach ◽  
Julia K. Rotow ◽  
Lincoln Harris ◽  
Franziska Haderk ◽  
...  

Author(s):  
Ashley Maynard ◽  
Caroline E. McCoach ◽  
Julia K. Rotow ◽  
Lincoln Harris ◽  
Franziska Haderk ◽  
...  

Lung cancer, the leading cause of cancer mortality, exhibits heterogeneity that enables adaptability, limits therapeutic success, and remains incompletely understood. Single-cell RNA sequencing (scRNAseq) of metastatic lung cancer was performed using 44 tumor biopsies obtained longitudinally from 27 patients before and during targeted therapy. Over 20,000 cancer and tumor microenvironment (TME) single-cell profiles exposed a rich and dynamic tumor ecosystem. scRNAseq of cancer cells illuminated targetable oncogenes beyond those detected clinically. Cancer cells surviving therapy as residual disease (RD) expressed an alveolar-regenerative cell signature suggesting a therapy-induced primitive cell state transition, whereas those present at on-therapy progressive disease (PD) upregulated kynurenine, plasminogen, and gap junction pathways. Active T-lymphocytes and decreased macrophages were present at RD and immunosuppressive cell states characterized PD. Biological features revealed by scRNAseq were biomarkers of clinical outcomes in independent cohorts. This study highlights how therapy-induced adaptation of the multi-cellular ecosystem of metastatic cancer shapes clinical outcomes.


Sign in / Sign up

Export Citation Format

Share Document